R(+)XK469 in Treating Patients With Advanced Neuroblastoma

You may be eligible if

• Histologically confirmed high-risk neuroblastoma that has relapsed or is refractory to standard therapy
• No active brain metastases
• * Previously treated brain metastases allowed if there is no requirement for corticosteroids or anticonvulsants
• Performance status - Karnofsky performance status 70-100% or Lansky score ≥ 70 for your pediatric patients
• More than 3 months
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Bilirubin normal (unless due to documented Gilbert's syndrome)
• Creatinine less than 1.5 times upper limit of normal
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other concurrent uncontrolled illness that would preclude study participation
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study participation
• No prior allergic reaction to compounds of similar chemical or biological composition to study drug (e.g., flurbiprofen or ibuprofen)
• No HIV-positive patients
• No concurrent biologic agents
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• No other concurrent chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No concurrent palliative radiotherapy
• See Disease Characteristics
• Recovered from all prior therapy
• No other concurrent investigational agents
• No concurrent commercial agents or therapies directed at malignancy
• No concurrent combination anti-retroviral therapy for HIV-positive patients